Comparable outcomes of HLA-matched unrelated and HLA-identical sibling donor bone marrow transplantation for childhood acute myeloid leukemia in first remission.
We retrospectively investigated the outcomes of HLA-matched unrelated BMT (MU-BMT, n = 13) and HLA-identical sibling donor BMT (MS-BMT, n = 17) for childhood AML in CR1 between June 2002 and August 2005. Engraftment of neutrophil and platelet did not differ between the two transplant groups. The cumulative incidence of grade II-IV acute GVHD and any chronic GVHD at three yr was not different between MS-BMT and MU-BMT. Of the 30 patients, four patients experienced relapses (three with MS-BMT, one with MU-BMT) and four patients died of transplant-related complications (two with MS-BMT, two with MU-BMT). A total of 23 patients survived with a median follow-up of 43.2 months. The Kaplan-Meier estimates for EFS rates at three yr were 71% and 77% for MS-BMT and MU-BMT, respectively, and the OS rates were 76% and 77% for MS-BMT and MU-BMT, respectively. The outcome of HLA-matched unrelated BMT is comparable to that of HLA-identical sibling BMT for childhood AML in CR1. HLA-matched unrelated BMT may be recommended for patients who have AML in CR1 without an HLA-matched sibling donor.
Lee
Dae-Hyoung
DH
Department of Pediatrics, College of Medicine, Hallym University, Seoul, Korea.
Kwon
Young-Joo
YJ
Lim
Jihyang
J
Kim
Yonggoo
Y
Han
Kyungja
K
Chung
Nak-Gyun
NG
Jeong
Dae-Chul
DC
Cho
Bin
B
Kim
Hack-Ki
HK
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006680:HLA Antigens / Q000378:metabolism*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D019520:Living Donors; D008297:Male; D009504:Neutrophils / Q000378:metabolism; D012074:Remission Induction; D012189:Retrospective Studies; D035781:Siblings; D016896:Treatment Outcome
D006680:HLA Antigens